Pfizer to shutter Indian site
This article was originally published in Scrip
Executive Summary
Pfizer's last remaining Indian manufacturing facility in Thane will be closed down from 16 September, the second recent plant-related action by a foreign firm after Sandoz said that it intended to discontinue operations at its Turbhe unit by the end of next year. Both facilities are located in the western state of Maharashtra.
You may also be interested in...
Pfizer Pulls Plug On Two Unviable Indian Sites, Over 1,500 Jobs At Risk
Pfizer is ending operations at two Indian manufacturing sites, including one with a checkered regulatory history. Approximately 1,700 jobs are at stake as a result of the action, though the US multinational clarified that it is not making a widespread exit from Indian manufacturing.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet